Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Other Non Operating Income (2020 - 2025)

Avalo Therapeutics (AVTX) has disclosed Other Non Operating Income for 6 consecutive years, with -$5000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Other Non Operating Income rose 99.9% year-over-year to -$5000.0, compared with a TTM value of $1.2 million through Jun 2025, up 124.58%, and an annual FY2024 reading of -$5000.0, up 88.1% over the prior year.
  • Other Non Operating Income was -$5000.0 for Q2 2025 at Avalo Therapeutics, down from $6.3 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $6.3 million in Q4 2024 and bottomed at -$5.0 million in Q2 2024.
  • Average Other Non Operating Income over 5 years is $116300.0, with a median of -$5000.0 recorded in 2021.
  • The sharpest move saw Other Non Operating Income plummeted 140.54% in 2021, then soared 3935.48% in 2024.
  • Year by year, Other Non Operating Income stood at -$15000.0 in 2021, then surged by 233.33% to $20000.0 in 2022, then skyrocketed by 675.0% to $155000.0 in 2023, then skyrocketed by 3935.48% to $6.3 million in 2024, then crashed by 100.08% to -$5000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for AVTX at -$5000.0 in Q2 2025, $6.3 million in Q4 2024, and -$5000.0 in Q3 2024.